1. Real-world data on the comparison of LDL-C lowering effects between alirocumab and evolocumab. (August 2022) Authors: Lin, D.-Y.; Tsai, C.-L.; Chuang, J.-Y.; Liang, C.-H.; Chen, Y.-H.; Chang, Y.-H.; Yeh, H.-I.; Lin, C.-F. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The current status of lipid control in elderly high-risk patients with dyslipidemia in Taiwan. (August 2022) Authors: Liang, C.-H.; Chang, Y.-H.; Tsai, C.-L.; Chuang, J.-Y.; Hsiao, C.-C.; Zeng, Y.-H.; Chen, Y.-H.; Yeh, H.-I.; Lin, C.-F. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Treatment of Type V dyslipoproteinemia: A rare phenotype of lipid disorders. (August 2022) Authors: Lin, C.-F.; Liang, C.-H.; Chuang, J.-Y.; Lin, D.-Y.; Tsai, C.-L.; Chen, Y.-H.; Yeh, H.-I.; Chang, Y.-H. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗